The Bristol-Myers–Squibb Deal May No Longer Be a Sure Thing, but It Will Still Likely Happen

The deal between Bristol-Myers Squibb (BMY) and Celgene (CELG) has been garnering plenty of headlines this week, and no matter what happens, there are likely to be plenty of people unhappy with the result.